A durable composite solution for modern façades, terraces, and garden spaces—replacing short-life materials with engineered WPC technology designed for real outdoor conditions.
God Incorporated AI Limited announced the launch of godincorporated.ai, a reflective AI chatbot and spiritual conversation app for seekers. The platform offers personalized dialogue, memory-aware reflection, and distinct mystical AI personae including Hathor and Moses. It emphasizes privacy and is designed for contemplative dialogue and spiritual inquiry.
HELSINKI, May 28, 2026 /PRNewswire/ -- Elisa Estonia has deployed Elisa Industriq's Gridle battery optimization solution across its mobile network to strengthen network resilience, while also enabling its base station batteries to contribute to balancing the Estonian electricity system...
PARIS, FRANCE, 28 MAI 2026 - Ipsen (Euronext : IPN ; ADR : IPSEY) a annoncé aujourd’hui la présentation de nouveaux résultats « late-breaking » issus de l’étude de phase III ELATIVE ® ainsi que de deux études en vie réelle lors du congrès de l’Association européenne pour l’étude du foie (EASL). Ensemble, ces données viennent conforter le corpus de preuves croissant établissant IQIRVO ® comme le seul traitement de deuxième ligne de la cholangite biliaire primitive (CBP) offrant une réduction rapide et robuste de la phosphatase alcaline (PAL), associée à une amélioration de la fatigue (chez les patients présentant une fatigue modérée à sévère à l'inclusion) ainsi qu'un soulagement du prurit.
PARIS, FRANCE, 28 MAY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) today announced the presentation of new late-breaking results from the ELATIVE ® Phase III trial and two real-world studies at the European Association for the Study of the Liver (EASL) congress. Together, these data further strengthen the growing body of evidence establishing IQIRVO ® as the only second-line primary biliary cholangitis (PBC) treatment providing rapid and robust alkaline phosphatase (ALP) reduction with fatigue improvement (in patients with moderate-to-severe fatigue at baseline) and pruritus relief.
Bottom line focus yields best Q1 profitability in company history
-Mews y SiteMinder son pioneros en la distribución nativa de primer nivel dentro del sistema operativo del hotel Con Mews Channel Manager, impulsado por SiteMinder, los líderes tecnológicos del sector hotelero se han unido para redefinir la forma en que los hoteles abordan la distribución....
US BARDA awarded Basilea USD 13.3 million to continue the development of Basilea’s novel oral antibiotic ceftibuten-ledaborbactam.
US BARDA hat Basilea USD 13.3 Millionen für die Entwicklung des neuartigen Antibiotikums Ceftibuten-Ledaborbactam bereitgestellt.
Schiphol, May 28, 2026 - Aegon today announces an agreement with its largest shareholder, Vereniging Aegon, on the future relationship with the Vereniging, alongside a proposed governance framework that will be put in place in connection with Aegon’s planned relocation to the US. Together, these steps are designed to align Aegon’s governance with US market standards and support the company’s ambition to become a leading US life insurance and retirement group.
May 28, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it will host a webinar, titled “R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis” on Tuesday, June 23, 2026, at 2:00pm ET.
Le venglustat de Sanofi a été accepté pour un examen prioritaire aux États-Unis afin de traiter la maladie de Gaucher de type 3